Holistic Management of Pulmonary Fibrosis: A Comprehensive Review Inés Palacio, Fernanda Hernández-González, Jacobo Sellarés, Jaume Bordas-Martinez Medicina Lithuania, 2026 Pulmonary fibrosis, encompassing idiopathic pulmonary fibrosis (IPF) and other fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (PPF), represents a group of chronic, life-threatening conditions associated with significant morbidity, mortality, and socioeconomic burden. Despite advances in antifibrotic therapies, traditional disease-centered management alone is insufficient to address the multidimensional needs of affected patients. This comprehensive review advocates for a holistic, patient-centered approach to the management of pulmonary fibrosis, integrating pharmacological interventions with systematic comorbidity assessment, pulmonary rehabilitation, psychosocial support, nutritional optimization, early palliative care, social and community reinforcement, and digital health technologies. We examine the evidence supporting each dimension of holistic care, discuss current barriers to implementation—including healthcare fragmentation, limited multidisciplinary protocols, and scarce resources—and outline future perspectives centered on precision medicine and integrated care models. By shifting from a purely organ-focused paradigm to a comprehensive, multidisciplinary strategy, clinicians can improve not only disease outcomes but also quality of life and overall well-being for patients living with fibrosing ILDs.
Mediastinal staging lymph node probability map in non-small cell lung cancer J. Bordas-Martinez, J.L. Vercher-Conejero, G. Rodriguez-González, P.C. Notta, C. Martin Cabeza, N. Cubero, R.M. Lopez-Lisbona, M. Diez-Ferrer, C. Tebé, S. Santos, M. Cortes-Romera, A. Rosell Respiratory Research, 2025 BACKGROUND: Mediastinal lymph node (LN) staging is routinely performed using PET/CT and EBUS-TBNA. Promising predictive algorithms for lymph nodes have been reported for each technique, both individually and in combination. This study aims to develop a predictive algorithm that combines EBUS, PET/CT and clinical data to provide a probability of malignancy. METHODS: A retrospective study was conducted on consecutive patients with non-small cell lung carcinoma staged using PET/CT and EBUS-TBNA. Lymph nodes were identified by level (N1, N2, and N3) and anatomical region (AR) (subcarinal, paratracheal, and hilar). A Standardized Uptake Value (SUV) was determined for each sampled LN. The ultrasound features collected included diameter in the short axis (DSA), morphology, border, echogenicity and the presence of the vascular hilum. A robust logistic regression model was used to construct an algorithm to estimate the probability of malignancy of the lymph node. RESULTS: A total of 116 patients with a mean age of 66, 93% of whom were men, were included. 358 lymph nodes were evaluated, 51% of which exhibited adenocarcinoma and 35% were squamous, while 14% were classified as non-small-cell lung carcinoma. The model estimated the probability of malignancy for each lymph node using age, DSA, SUVmax, and AR. The Area Under the ROC curve, was 0.89. A user-friendly application was also developed ( https://ubidi.shinyapps.io/lymma/ .) CONCLUSIONS: The integration of patient clinical characteristics, EBUS features, and PET/CT findings may generate a pre-sampling malignancy probability map for each lymph node. The model requires prospective and external validation.
A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study Mireia Baiges, David Iglesias, Sara Persentili, Marta Jiménez, Pilar Ortega, Jaume Bordas-Martinez Medicina Lithuania, 2025 Background and Objectives: Specialized nurses play an essential role in managing pulmonary fibrosis. While tele-nursing has the potential to optimize disease management, current evidence regarding its impact remains limited. This study aimed to evaluate a tele-nursing intervention that provided unscheduled access to a specialized nurse via phone or email for both patients and caregivers. Materials and Methods: This was a prospective, single-center, open-label, and pre–post pilot study. Participants and their caregivers were provided with direct access to a specialized nurse, by phone and email, for unscheduled consultations. Patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs) were collected at baseline and after three months of tele-nursing access. PREMs were assessed using a 10-point Likert scale questionnaire, and PROMs were evaluated using the King’s Brief Interstitial Lung Disease (K-BILD) and the Living with Pulmonary Fibrosis (L-PF) questionnaires. Results: A total of 47 patients with pulmonary fibrosis receiving antifibrotic drugs were enrolled. At three months, 44 patients and 34 caregivers completed the questionnaires. Four patients did not complete the study due to death, lung transplantation, or transition to end-of-life care. No significant changes were observed in PROMs. However, PREMs showed significant improvements, with most scores exceeding 9/10. Patient satisfaction increased by 28% (p < 0.001), and caregiver satisfaction by 30% (p < 0.001). Caregivers of patients who did not complete the study also reported high satisfaction, comparable to that of other caregivers. Conclusions: A pragmatic and affordable tele-nursing program, based on direct phone and email consultations, may enhance patient and caregiver satisfaction in the management of pulmonary fibrosis.
Viability of a new home program of forced spirometry with bronchodilator response measurement in the assessment of patients with asthma Héctor Cabrerizo Carreño, Cristina Bellver Asperilla, Ana Maria Romero-Ortiz, Salud Santos, Samantha Aso-González, Jaume Bordas-Martinez, Nuria Fabrellas, Eva Maria Guix-Comellas, Guillermo Suarez-Cuartin, Mariana Muñoz-Esquerre Multidisciplinary Respiratory Medicine, 2025 Background: Home spirometry using portable devices offers a potential alternative for asthma management by reducing hospital dependence and improving accessibility. This study aimed to assess the feasibility of a home spirometry program with bronchodilator response (BDR) testing performed without direct medical supervision. Methods: A prospective observational study was conducted with 47 asthma patients from a tertiary hospital. Participants received clear instructions and performed forced spirometry with BDR testing at home using a portable device. The primary outcomes included spirometry quality, variability compared to hospital tests, and patient satisfaction. Results: A total of 78% of participants achieved high-quality spirometry (A or B, according to ATS/ERS criteria), despite greater variability in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) compared to hospital tests. However, the results remained clinically acceptable. Patients reported high satisfaction with the device, highlighting its ease of use and convenience. Conclusions: Home spirometry with BDR testing is a feasible tool for asthma follow-up, maintaining acceptable quality while reducing hospital-based testing. Although improvements are needed to minimize variability and enhance consistency, this program has the potential to optimize asthma management, increase accessibility, and reduce the burden on healthcare facilities.
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial Guadalupe Bermudo-Peloche, Belén Del Rio, Vanesa Vicens-Zygmunt, Jaume Bordas-Martinez, Marta Hernández, Claudia Valenzuela, Rosalía Laporta, Juan Rigual Bobillo, Karina Portillo, Paloma Millán-Billi, Eva Balcells, Diana Badenes-Bonet, Santi Bolivar, José-Antonio Rodríguez-Portal, Cecilia López Ramirez, Laura Tomás, Koral Fernández de Roitegi, Jacobo Sellarés, Diego Castillo, Jessica González, Silvia Barril, Yasmina Gutiérrez-Rodríguez, Paloma Caballero, Javier Alarcon, Judith Peñafiel, Jose Sanz-Santos, Rosana Blavia, Cristina Caupena, Pilar Segovia, Salud Santos-Pérez, Anna Ferrer-Artola, Maria B. Badia, Pilar Hereu, Mireya Fuentes, Ana Montes-Worboys, Tomás Franquet, Patricio Luburich, María Molina-Molina European Respiratory Journal, 2025 BackgroundPatients with severe COVID-19 may develop lung fibrosis. Pirfenidone is an anti-fibrotic drug approved for idiopathic pulmonary fibrosis. The efficacy and safety of pirfenidone in patients with fibrotic interstitial lung changes after recovery from severe COVID-19 pneumonia were evaluated.MethodsThis was a phase 2, double-blind, placebo-controlled, Spanish multicentre clinical trial. Patients were randomised to receive pirfenidone or placebo (2:1) for 24 weeks. The primary end-point was the proportion of patients that improved, considered when percentage change in forced vital capacity (FVC) was ≥10% and/or any reduction in the fibrotic score on chest high-resolution computed tomography (HRCT). Secondary end-points included health-related quality of life (HRQoL), exercise capacity and drug safety profile.ResultsFrom 119 eligible patients, 113 were randomised and 103 were analysed (pirfenidone n=69 and placebo n=34). Most patients were male (73.5%) and were receiving low-dose prednisone; mean age was 63.7 years and mean body mass index was 29 kg·m−2. The percentage of patients that improved was similar in the pirfenidone and placebo groups (79.7%versus82.3%, respectively). The mean predicted FVC increased by 12.74±20.6% with pirfenidone and 4.35±22.3% with placebo (p=0.071), and the HRCT (%) fibrotic score decreased by 5.44±3.69% with pirfenidone and 2.57±2.59% with placebo (p=0.52). Clinically meaningful improvement in HRQoL was not statistically different (55.2% in the pirfenidone group and 39.4% in the placebo group). Exercise capacity, adverse events and hospitalisations were similar between groups. No deaths were reported.ConclusionsThe overall improvements in lung function and HRCT fibrotic score after 6 months with pirfenidone were not significantly different than with placebo.
Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF Jaume Bordas-Martinez, Neus Salord, Vanesa Vicens-Zygmunt, João Carmezim, Sandra Pérez, Eliseo Prado, María Calvo, Rosana Blavia, Guadalupe Bermudo, Salud Santos, Carmen Monasterio, María Molina-Molina Respiratory Research, 2024 Introduction Sleep-disordered breathing (SDB) is a major comorbidity in idiopathic pulmonary fibrosis (IPF) and is associated with a poor outcome. There is a lack of knowledge regarding the impact of SDB treatment on IPF. We assessed at one year: (1) the effect of CPAP and/or nocturnal oxygen therapy on IPF regarding lung function, blood mediators, and quality of life; (2) adherence to SDB treatment and SDB changes. Methodology This is a prospective study of consecutive newly diagnosed IPF patients initiating anti-fibrotic treatment. Lung function, polysomnography, blood tests and quality of life questionnaires were performed at inclusion and after one year. Patients were classified as obstructive sleep apnoea (OSA), central sleep apnoea (CSA), and sleep-sustained hypoxemia (SSH). SDB therapy (CPAP and/or nocturnal oxygen therapy) was initiated if needed. Results Fifty patients were enrolled (36% had OSA, 22% CSA, and 12% SSH). CPAP was started in 54% of patients and nocturnal oxygen therapy in 16%. At one-year, polysomnography found improved parameters, though 17% of patients had to add nocturnal oxygen therapy or CPAP, while 33% presented SDB onset at this second polysomnography. CPAP compliance at one year was 6.74 h/night (SD 0.74). After one year, matrix metalloproteinase-1 decreased in OSA and CSA (p = 0.029; p = 0.027), C-reactive protein in OSA (p = 0.045), and surfactant protein D in CSA group (p = 0.074). There was no significant change in lung function. Conclusions Treatment of SBD with CPAP and NOT can be well tolerated with a high compliance. IPF patients may exhibit SDB progression and require periodic re-assessment. Further studies to evaluate the impact of SDB treatment on lung function and serological mediators are needed.
Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: A systematic review Jaume Bordas-Martinez, Jelle R. Miedema, Bas J. Mathot, Leonard Seghers, Robert-Jan H. Galjaard, Marc H.G.P. Raaijmakers, Anna M. Aalbers, Marlies Wijsenbeek, Maria Molina-Molina, Merel E. Hellemons Jhlt Open, 2024 Background: Lung transplantation (LTX) is the last life-extending option for patients with progressive fibrosing interstitial lung diseases (fILD). Between 12% and 71% of patients with fILD are patients with underlying telomere-dysfunction (trILD) related to pathogenic telomere-related gene (TRG) variants and/or short telomere length. TrILD patients tend to have earlier disease onset, faster progression, and worse prognosis causing them to be referred for LTX more often. Regarding LTX outcomes in trILD, there are contradictory reports on patient and graft survival, as well as numerous other outcomes. There is no consensus on whether trILD is associated with poorer outcomes after LTX and what considerations regarding candidacy are appropriate. Methods: We aimed to systematically review LTX outcomes of patients with trILD in comparison to those with non-trILD. Results: A systematic literature search yielded 13 studies that met the inclusion criteria including 933 LTX, 281 in trILD, and 652 in non-trILD. Despite large heterogeneity in the methodological study quality and reported outcomes among the studies, patient and graft survival after LTX in trILD did not evidently seem inferior to LTX in non-trILD. However, there may be increased risk of specific complications, such as cytopenias, airway complications, and cytomegalovirus-reactivation. Conclusions: for LTX. On top of limited available high-quality data, specific patient selection and post-transplant management strategies may affect the currently acquired results. As such, differences may exist regarding transplant-related outcomes, which could require special attention and consideration. Further high-quality comparative studies on LTX outcomes in trILD are needed to draw final conclusions and provide recommendations regarding patient selection and post-transplantation management.
Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study Esteban Cano-Jiménez, Ana Villar Gómez, Eduardo Velez Segovia, Myriam Aburto Barrenechea, Jacobo Sellarés Torres, Joel Francesqui, Karina Portillo Carroz, Alan Jhunior Solis Solis, Orlando Acosta Fernández, Ana Belén Llanos González, Jaume Bordas-Martinez, Eva Cabrera Cesar, Eva Balcells Vilarnau, Diego Castillo Villegas, Ana Reyes Pardessus, Coral González Fernández, Marta García Moyano, Amaia Urrutia Gajate, Andrés Blanco Hortas, María Molina-Molina Erj Open Research, 2024 BackgroundFibrotic hypersensitivity pneumonitis (fHP) is an immune-mediated interstitial lung disease caused by sensitisation to chronic allergen inhalation. This study aimed to determine prognostic indicators of progression and mortality in fHP.MethodsThis was a retrospective, multicentre, observational, cross-sectional cohort study of consecutive patients diagnosed with fHP from 1 January 2012 to 31 December 2021. Multivariate Cox regression analyses were used to calculate hazard ratios (HRs) with 95% confidence intervals for predictors of progression and survival.ResultsA total of 403 patients were diagnosed with fHP: median (interquartile range) age 66.5 (14.0) years, 51.9% females and 55.1% never-smokers. The cause of fHP was mainly fungal (39.7%) or avian (41.4%). Lung biopsy was performed in 269 cases (66.7%). In the whole cohort the variables that were related to mortality or lung transplant were older age (HR 1.08; p<0.001), percentage predicted forced vital capacity (HR 0.96; p=0.001), lymphocytosis in bronchoalveolar lavage (BAL) (HR 0.93; p=0.001), presence of acute exacerbation during follow-up (HR 3.04; p=0.001) and GAP (gender, age and lung physiology) index (HR 1.96; p<0.01). In the group of biopsied patients, the presence of fibroblastic foci at biopsy (HR 8.39; p<0.001) stands out in multivariate Cox regression analyses as a highly significant predictor for increased mortality or lung transplant. GAP index (HR 1.26; p=0.009), lymphocytosis in BAL (HR 0.97; p=0.018) and age (HR 1.03; p=0.018) are also predictors of progression.ConclusionsThe study identified several prognostic factors for progression and/or survival in fHP. The presence of fibroblastic foci at biopsy was a consistent predictor for increased mortality and the presence of lymphocytosis in BAL was inversely related to mortality.
Characterization of Sleep-Disordered Breathing in Idiopathic Pulmonary Fibrosis Jaume Bordas-Martinez, Neus Salord, Vanesa Vicens-Zygmunt, Sandra Pérez, Eliseo Prado, María Calvo, Rosana Blavia, Guadalupe Bermudo, Ana Montes-Worboys, Salud Santos, Carmen Monasterio, María Molina-Molina Archivos De Bronconeumologia, 2023
Characteristics of long-COVID among older adults: a cross-sectional study Vered Daitch, Dana Yelin, Muhammad Awwad, Giovanni Guaraldi, Jovana Milić, Cristina Mussini, Marco Falcone, Giusy Tiseo, Laura Carrozzi, Francesco Pistelli, Mayssam Nehme, Idris Guessous, Laurent Kaiser, Pauline Vetter, Jaume Bordas-Martínez, Xavier Durà-Miralles, Dolores Peleato-Catalan, Carlota Gudiol, Irit Shapira-Lichter, Donna Abecasis, Leonard Leibovici, Dafna Yahav, Ili Margalit International Journal of Infectious Diseases, 2022 OBJECTIVES: To describe long-COVID symptoms among older adults and to assess the risk factors for two common long-COVID symptoms: fatigue and dyspnea. METHODS: This is a multicenter, prospective cohort study conducted in Israel, Switzerland, Spain, and Italy. Individuals were included at least 30 days after their COVID-19 diagnosis. We compared long-COVID symptoms between elderly (aged >65 years) and younger individuals (aged 18-65 years) and conducted univariate and multivariable analyses for the predictors of long-COVID fatigue and dyspnea. RESULTS: A total of 2333 individuals were evaluated at an average of 5 months (146 days [95% confidence interval 142-150]) after COVID-19 onset. The mean age was 51 years, and 20.5% were aged >65 years. Older adults were more likely to be symptomatic, with the most common symptoms being fatigue (38%) and dyspnea (30%); they were more likely to complain of cough and arthralgia and have abnormal chest imaging and pulmonary function tests. Independent risk factors for long-COVID fatigue and dyspnea included female gender, obesity, and closer proximity to COVID-19 diagnosis; older age was not an independent predictor. CONCLUSION: Older individuals with long-COVID have different persisting symptoms, with more pronounced pulmonary impairment. Women and individuals with obesity are at risk. Further research is warranted to investigate the natural history of long-COVID among the elderly population and to assess possible interventions aimed at promoting rehabilitation and well-being.
Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study Dana Yelin, Ili Margalit, Mayssam Nehme, Jaume Bordas-Martínez, Francesco Pistelli, Dafna Yahav, Idris Guessous, Xavier Durà-Miralles, Laura Carrozzi, Irit Shapira-Lichter, Pauline Vetter, Dolores Peleato-Catalan, Giusy Tiseo, Eytan Wirtheim, Laurent Kaiser, Carlota Gudiol, Marco Falcone, Leonard Leibovici, and Journal of Clinical Medicine, 2022
Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis Carmen Herranz, Francesca Mateo, Alexandra Baiges, Gorka Ruiz de Garibay, Alexandra Junza, Simon R Johnson, Suzanne Miller, Nadia García, Jordi Capellades, Antonio Gómez, August Vidal, Luis Palomero, Roderic Espín, Ana I Extremera, Eline Blommaert, Eva Revilla‐López, Berta Saez, Susana Gómez‐Ollés, Julio Ancochea, Claudia Valenzuela, Tamara Alonso, Piedad Ussetti, Rosalía Laporta, Antoni Xaubet, José A Rodríguez‐Portal, Ana Montes‐Worboys, Carlos Machahua, Jaume Bordas, Javier A Menendez, Josep M Cruzado, Roser Guiteras, Christophe Bontoux, Concettina La Motta, Aleix Noguera‐Castells, Mario Mancino, Enrique Lastra, Raúl Rigo‐Bonnin, Jose C Perales, Francesc Viñals, Alvaro Lahiguera, Xiaohu Zhang, Daniel Cuadras, Coline H M van Moorsel, Joanne J van der Vis, Marian J R Quanjel, Harilaos Filippakis, Razq Hakem, Chiara Gorrini, Marc Ferrer, Aslihan Ugun‐Klusek, Ellen Billett, Elżbieta Radzikowska, Álvaro Casanova, María Molina‐Molina, Antonio Roman, Oscar Yanes, Miquel A Pujana EMBO Molecular Medicine, 2021
Holistic Management of Pulmonary Fibrosis: A Comprehensive Review I Palacio, F Hernández-González, J Sellarés, J Bordas-Martinez Medicina 62 (5), 817 , 2026 2026
A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changes M Hernandez-Argudo, J Bordas-Martinez, V Vicens-Zygmunt, G Bermudo, ... Respiratory Research , 2026 2026
Improving Satisfaction in Pulmonary Fibrosis Patients and Caregivers: The Impact of Tele-nursing M Baiges, D Iglesias, M Jiménez, Y Galea, M Clarambo, L Lahuerta, ... European Respiratory Journal 66 (suppl 69) , 2025 2025
A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study M Baiges, D Iglesias, S Persentili, M Jiménez, P Ortega, ... Medicina 61 (8), 1385 , 2025 2025 Citations: 1
Viability of a new home program of forced spirometry with bronchodilator response measurement in the assessment of patients with asthma H Cabrerizo-Carreño, CB Asperilla, AM Romero-Ortiz, S Santos, ... Multidisciplinary Respiratory Medicine 20 (1), 1024 , 2025 2025 Citations: 1
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial G Bermudo-Peloche, B Del Rio, V Vicens-Zygmunt, J Bordas-Martinez, ... European Respiratory Journal 65 (4), 2402249 , 2025 2025 Citations: 18
Mediastinal staging lymph node probability map in non-small cell lung cancer J Bordas-Martinez, JL Vercher-Conejero, G Rodriguez-González, ... Respiratory Research 26 (1), 113 , 2025 2025 Citations: 2
Impacto clínico y biológico de los trastornos respiratorios del sueño en la fibrosis pulmonar idiopática J Bordas Martínez Universitat de Barcelona , 2024 2024
Predictive biomarkers of persistent interstitial changes after COVID19 MH Argudo, G Bermudo, VV Zygmunt, GS Cuartín, CM Montaño, ... European Respiratory Journal 64 (suppl 68) , 2024 2024
Impact and prevalence of alpha-1 antitrypsin deficiency in different lung diseases NA Sellés, YG Colón, AM Ausiró, JB Martinez, MB Badia, SM Acosta, ... European Respiratory Journal 64 (suppl 68) , 2024 2024
Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF J Bordas-Martinez, N Salord, V Vicens-Zygmunt, J Carmezim, S Pérez, ... Respiratory Research 25 (1), 247 , 2024 2024 Citations: 8
Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: a systematic review J Bordas-Martinez, JR Miedema, BJ Mathot, L Seghers, RJH Galjaard, ... JHLT open 3, 100054 , 2024 2024 Citations: 12
Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study E Cano-Jiménez, A Villar Gómez, E Velez Segovia, ... ERJ open research 10 (1), 00405-2023 , 2024 2024 Citations: 14
Characterization of sleep-disordered breathing in idiopathic pulmonary fibrosis J Bordas-Martinez, N Salord, V Vicens-Zygmunt, S Pérez, E Prado, ... Archivos de bronconeumologia 59 (11), 768-771 , 2023 2023 Citations: 7
Physical exercise in post-COVID patients JB Martinez, P Carrasco, M Berga, F López, H Sanchis-Gilabert, ... European Respiratory Journal 62 (suppl 67) , 2023 2023
Real-world of Nintedanib in a Spanish non-IPF progressive pulmonary fibrosis cohort VV Zygmunt, J Bordas-Martínez, M Muñoz-Bolaño, J Carmezim-Correia, ... European Respiratory Journal 62 (suppl 67) , 2023 2023 Citations: 1
Relevance of the systematic sleep study on idiopathic pulmonary fibrosis (IPF) JB Martinez, NS Oleo, VV Zygmunt, RB Aloy, SP Ramos, EP Gala, ... European Respiratory Journal 62 (suppl 67) , 2023 2023
SAFETY PROFILE OF PIRFENIDONE IN COVID19 RESPIRATORY DISTRESS SYNDROME MH Argudo, GB Peloche, MM Molina, VV Zygmunt, GS Cuartin, ... European Respiratory Journal 62 (suppl 67) , 2023 2023
Pirfenidone in post-covid19 pulmonary fibrosis (FIBRO-COVID): Phase-II randomized clinical trial (NCT04607928) GB Peloche, B Del Río, V Vicens-Zygmunt, C Valenzuela, R Laporta, ... European Respiratory Journal 62 (suppl 67) , 2023 2023 Citations: 1
Is the long-term mortality similar in COVID-19 and community-acquired pneumonia? R Méndez, P González-Jiménez, A Latorre, N Mengot, R Zalacain, ... Frontiers in medicine 10, 1236142 , 2023 2023 Citations: 5
MOST CITED SCHOLAR PUBLICATIONS
Characteristics of long-COVID among older adults: a cross-sectional study V Daitch, D Yelin, M Awwad, G Guaraldi, J Milić, C Mussini, M Falcone, ... International journal of infectious diseases 125, 287-293 , 2022 2022 Citations: 96
Patterns of long COVID symptoms: a multi-center cross sectional study D Yelin, I Margalit, M Nehme, J Bordas-Martínez, F Pistelli, D Yahav, ... Journal of clinical medicine 11 (4), 898 , 2022 2022 Citations: 66
Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers JG Shull, MT Pay, C Lara Compte, M Olid, G Bermudo, K Portillo, ... Respirology 26 (4), 352-359 , 2021 2021 Citations: 27
Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis C Herranz, F Mateo, A Baiges, G Ruiz de Garibay, A Junza, SR Johnson, ... EMBO Molecular Medicine 13 (9), EMMM202113929 , 2021 2021 Citations: 19
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial G Bermudo-Peloche, B Del Rio, V Vicens-Zygmunt, J Bordas-Martinez, ... European Respiratory Journal 65 (4), 2402249 , 2025 2025 Citations: 18
Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study E Cano-Jiménez, A Villar Gómez, E Velez Segovia, ... ERJ open research 10 (1), 00405-2023 , 2024 2024 Citations: 14
Effects of early physical therapy and follow-up in acute severe coronavirus disease 2019 pneumonia: A retrospective observational study J Bordas-Martínez, A Luzardo-González, A Arencibia, F Tormo, L Matéu, ... Frontiers in medicine 9, 866055 , 2022 2022 Citations: 13
Outcomes of lung transplantation in patients with telomere-related forms of progressive fibrosing interstitial lung disease pulmonary fibrosis: a systematic review J Bordas-Martinez, JR Miedema, BJ Mathot, L Seghers, RJH Galjaard, ... JHLT open 3, 100054 , 2024 2024 Citations: 12
Idiopathic pulmonary fibrosis cluster analysis highlights diagnostic delay and cardiovascular comorbidity association with outcome J Bordas-Martínez, R Gavaldà, JG Shull, V Vicens-Zygmunt, ... ERJ open research 7 (2) , 2021 2021 Citations: 10
Radio-histological correlation of lung features in severe COVID-19 through CT-scan and lung ultrasound evaluation P Trias-Sabrià, E Dorca Duch, M Molina-Molina, S Aso, M Díez-Ferrer, ... Frontiers in medicine 9, 820661 , 2022 2022 Citations: 9
Treating sleep-disordered breathing of idiopathic pulmonary fibrosis patients with CPAP and nocturnal oxygen treatment. A pilot study: Sleep-disordered breathing treatment in IPF J Bordas-Martinez, N Salord, V Vicens-Zygmunt, J Carmezim, S Pérez, ... Respiratory Research 25 (1), 247 , 2024 2024 Citations: 8
Characterization of sleep-disordered breathing in idiopathic pulmonary fibrosis J Bordas-Martinez, N Salord, V Vicens-Zygmunt, S Pérez, E Prado, ... Archivos de bronconeumologia 59 (11), 768-771 , 2023 2023 Citations: 7
Is the long-term mortality similar in COVID-19 and community-acquired pneumonia? R Méndez, P González-Jiménez, A Latorre, N Mengot, R Zalacain, ... Frontiers in medicine 10, 1236142 , 2023 2023 Citations: 5
Patient-reported outcomes measures (PROMs) and patient-reported experience measures (PREMs) of COVID-19 telerehabilitation: Prospective pilot program J Bordas-Martinez, LM Gómez, DC Menoyo, M López-Sánchez, S Santos, ... Medicine 101 (31), e29639 , 2022 2022 Citations: 4
Experience with nintedanib in severe pulmonary fibrosis associated with systemic sclerosis: a case series J Bordas-Martinez, AB Llanos-González, R Jodar-Masanes, ... Open Respiratory Archives 3 (1), 100080 , 2021 2021 Citations: 4
Telemedicine home CPAP titration and follow-up in the COVID-19 scenario J Bordas-Martinez, N Salord, E Fontanilles, E Prado, M Calvo, ... ERJ Open Research 8 (4) , 2022 2022 Citations: 3
Mediastinal staging lymph node probability map in non-small cell lung cancer J Bordas-Martinez, JL Vercher-Conejero, G Rodriguez-González, ... Respiratory Research 26 (1), 113 , 2025 2025 Citations: 2
N3 hilar sampling decision in the staging of mediastinal lung cancer J Bordas-Martinez, JL Vercher-Conejero, G Rodriguez-González, ... ERJ Open Research 7 (3) , 2021 2021 Citations: 2
A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study M Baiges, D Iglesias, S Persentili, M Jiménez, P Ortega, ... Medicina 61 (8), 1385 , 2025 2025 Citations: 1
Viability of a new home program of forced spirometry with bronchodilator response measurement in the assessment of patients with asthma H Cabrerizo-Carreño, CB Asperilla, AM Romero-Ortiz, S Santos, ... Multidisciplinary Respiratory Medicine 20 (1), 1024 , 2025 2025 Citations: 1
